Lifesci Capital Has Optimistic Outlook of MLTX Q4 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Stock analysts at Lifesci Capital raised their Q4 2025 EPS estimates for shares of MoonLake Immunotherapeutics in a report released on Sunday, February 22nd. Lifesci Capital analyst R. Katkhuda now anticipates that the company will earn ($0.90) per share for the quarter, up from their prior forecast of ($1.14). The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

A number of other equities analysts have also issued reports on the company. UBS Group set a $24.00 price target on MoonLake Immunotherapeutics in a report on Friday, January 9th. Needham & Company LLC increased their price objective on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, February 3rd. Citigroup cut MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research note on Wednesday, October 29th. Finally, The Goldman Sachs Group downgraded MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and increased their price target for the stock from $8.00 to $10.00 in a report on Wednesday, January 14th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and an average target price of $27.15.

MoonLake Immunotherapeutics Trading Down 2.6%

NASDAQ MLTX opened at $18.20 on Wednesday. The firm’s fifty day moving average is $15.38 and its two-hundred day moving average is $23.61. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50. The firm has a market cap of $1.17 billion, a PE ratio of -5.48 and a beta of 1.21.

Institutional Trading of MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MLTX. Cormorant Asset Management LP lifted its holdings in MoonLake Immunotherapeutics by 118.4% in the 4th quarter. Cormorant Asset Management LP now owns 4,355,433 shares of the company’s stock valued at $57,405,000 after purchasing an additional 2,361,260 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of MoonLake Immunotherapeutics by 18,782.8% during the 4th quarter. Janus Henderson Group PLC now owns 2,095,988 shares of the company’s stock worth $27,657,000 after purchasing an additional 2,084,888 shares during the last quarter. Logos Global Management LP purchased a new stake in shares of MoonLake Immunotherapeutics during the fourth quarter worth about $23,065,000. Alliancebernstein L.P. grew its holdings in shares of MoonLake Immunotherapeutics by 17.8% during the second quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company’s stock worth $53,715,000 after buying an additional 171,932 shares in the last quarter. Finally, Vivo Capital LLC acquired a new position in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $13,180,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

Insider Buying and Selling

In related news, CEO Da Silva Jorge Santos sold 130,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the sale, the chief executive officer owned 2,948,577 shares of the company’s stock, valued at approximately $44,464,541.16. This represents a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kristian Reich sold 130,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the transaction, the insider directly owned 72,908 shares of the company’s stock, valued at $1,099,452.64. The trade was a 64.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 402,908 shares of company stock valued at $5,987,162. Corporate insiders own 12.05% of the company’s stock.

Key MoonLake Immunotherapeutics News

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Strong phase‑2 efficacy drove investor enthusiasm — sonelokimab showed high response rates in axSpA/chronic back‑pain programs (reported ~81% ASAS40 at Week 12) and S‑OLARIS data were highlighted at Investor Day, supporting the drug’s multi‑indication potential. MoonLake stock surges on positive axSpA trial data
• Positive Sentiment: Separate reports emphasize Phase‑2 chronic back pain success, which helped pre‑market gains and bolstered confidence into Investor Day. MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain
• Neutral Sentiment: Multiple analysts raised price targets and kept buy ratings (BTIG to $30, Needham to $25; other outlets reported increases), reflecting upside expectations if late‑stage programs progress. Benzinga analyst coverage
• Neutral Sentiment: Company released Investor Day materials (slides and transcript) and highlighted S‑OLARIS updates and program priorities — useful for modeling but not immediately dilutive. MoonLake Analyst/Investor Day – Slideshow
• Neutral Sentiment: Quarterly results showed EPS of ($0.97), in line with consensus but still a cash‑burning profile; that met expectations but leaves funding and profitability questions for longer‑term holders. Earnings press release
• Negative Sentiment: Mixed phase‑3 hidradenitis suppurativa (HS) readouts: VELA‑2 missed its primary endpoint, prompting at least one downgrade (Strong Buy → Buy). Although the FDA Type B meeting leaves a pathway to file a BLA using pooled data, the VELA‑2 miss increases regulatory and commercial execution risk. MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.